Afanat (Afatinib) 40mg Tablets | Natco Generic EGFR Inhibitor | GLT

Generic Information: Afanat (Afatinib) — Natco, India

Afanat is a generic formulation of afatinib manufactured by Natco Pharma Limited, one of India's most established producers of oncology generics. Supplied as 40 mg film-coated tablets in a 28-tablet bottle, Afanat offers a cost-effective alternative to the originator brand for patients with EGFR-mutant non-small cell lung cancer. Natco's reputation is built on decades of manufacturing high-quality, internationally recognized cancer generics, and Afanat carries the same 40 mg strength and once-daily dosing as the reference product.

What Is Afanat (Afatinib) Used For?

Afanat is used to treat non-small cell lung cancer with activating EGFR mutations, including exon 19 deletions and the L858R point mutation, as well as uncommon mutations such as G719X, L861Q and S768I. It is a first-line option for EGFR-mutant NSCLC and is also used in squamous NSCLC that has progressed after platinum-based chemotherapy, mirroring the approved indications of the originator afatinib.

How Does Afanat (Afatinib) Work?

Afanat contains afatinib, an irreversible pan-ErbB tyrosine kinase inhibitor. By covalently binding the kinase domains of EGFR, HER2 and ErbB4, it permanently blocks the growth signals that drive EGFR-mutant lung cancer. This mechanism gives afatinib durable activity and makes it effective against certain uncommon mutations that reversible first-generation inhibitors cannot adequately target.

Indications

Afanat is indicated for the treatment of adults with locally advanced or metastatic non-small cell lung cancer harboring non-resistant EGFR mutations, and for metastatic squamous NSCLC progressing on or after platinum-based chemotherapy. EGFR mutation testing is required before starting treatment.

Dosage

The recommended dose of Afanat is 40 mg once daily, taken at least one hour before or two hours after a meal. The 28-tablet bottle provides one month of therapy at the standard dose. Dose reductions to 30 mg may be considered for tolerability, and treatment should be supervised by an oncologist experienced in managing EGFR-targeted therapy.

Side Effects

Afanat shares the safety profile of afatinib: the most common side effects are diarrhea, acneiform rash, stomatitis, paronychia, dry skin, and reduced appetite. Serious reactions such as interstitial lung disease, liver toxicity and severe skin reactions are uncommon but require prompt medical attention. Early and proactive management of diarrhea and skin symptoms helps patients remain on treatment.

Storage

Store Afanat in a cool, dry place away from direct sunlight and moisture, in its original bottle. Keep out of reach of children and swallow tablets whole with water.

Why Choose the GLT?

Afanat through GLT brings the trusted Natco generic to patients and institutions at a fraction of the originator's Western price, with the reliability of a Hong Kong-licensed supply channel. We source genuine, properly stored stock and provide the documentation needed for informed cross-border purchasing. For those seeking a proven, affordable afatinib without compromising on the molecule or the dose, Afanat is a practical, dependable choice.

How to Order Afanat (Afatinib)

Contact us on WhatsApp at +86 15234153837 or by email at [email protected] to place an order. Specify the quantity and your destination, and we will confirm stock, pricing and delivery arrangements.

FAQ

Is Afanat the same as Gilotrif? Afanat is a generic of Gilotrif — both contain afatinib 40 mg with the same dosing, but Afanat is produced by Natco Pharma rather than the originator.

Is Afanat available in a 30 mg strength? Afanat is available in multiple strengths; this listing covers the 40 mg, 28-tablet bottle, which is the standard monthly dose.

How long does a 28-tablet bottle last? At 40 mg once daily, one bottle provides 28 days — approximately one month of treatment.

Do I need a prescription for Afanat? Yes, afatinib is a prescription oncology medicine and should be used under the supervision of a physician.